Počet záznamů: 1
Aurora kinase inhibitors: Progress towards the clinic
- 1.
SYSNO ASEP 0377543 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Aurora kinase inhibitors: Progress towards the clinic Tvůrce(i) Kollareddy, M. (CZ)
Zheleva, D. (GB)
Dzubak, P. (CZ)
Brahmkshatriya, Pathik (UOCHB-X)
Lepšík, Martin (UOCHB-X) RID, ORCID
Hajduch, M. (CZ)Celkový počet autorů 6 Zdroj.dok. Investigational New Drugs. - : Springer - ISSN 0167-6997
Roč. 30, č. 6 (2012), s. 2411-2432Poč.str. 22 s. Jazyk dok. eng - angličtina Země vyd. US - Spojené státy americké Klíč. slova Aurora kinases ; cancer ; inhibitors Vědní obor RIV CF - Fyzikální chemie a teoretická chemie CEZ AV0Z40550506 - UOCHB-X (2005-2011) UT WOS 000310470100036 DOI 10.1007/s10637-012-9798-6 Anotace The Aurora kinases (serine/threonine kinases) were discovered in 1995 during studies of mutant alleles associated with abnormal spindle pole formation in Drosophila melanogaster. They soon became the focus of much attention because of their importance in human biology and association with cancer. Aurora kinases are essential for cell division and are primarily active during mitosis. Following their identification as potential targets for cancer chemotherapy, many Aurora kinase inhibitors have been discovered and developed. Currently, there are about 30 Aurora kinase inhibitors in different stages of pre-clinical and clinical development. This review summarizes the characteristics and status of Aurora kinase inhibitors in preclinical, Phase I, and Phase II clinical studies, with particular emphasis on the mechanisms of action and resistance to these promising anticancer agents. Pracoviště Ústav organické chemie a biochemie Kontakt asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Viktorie Chládková, Tel.: 232 002 434 Rok sběru 2013
Počet záznamů: 1